옵션 체인은 다양한 행사가격과 만기일에 대한 NRX Pharmaceuticals의 주식 옵션 주요 데이터를 보여줍니다. 트레이더들은 이 정보를 사용하여 잠재적 거래를 분석하고 NRX Pharmaceuticals에 대한 시장 심리를 평가합니다..

NRX Pharmaceuticals (NASDAQ:NRXP) 주식, 옵션 체인

NRX PHARMACEUTICALS INC

NRX Pharmaceuticals

NRX Pharmaceuticals Inc is a clinical-stage, small-molecule pharmaceutical company that develops and plans to distribute novel therapeutics for the treatment of central nervous system disorders and life-threatening pulmonary diseases. It has announced the commercialization of ZYESAMI (Aviptadil), an application for COVID-related respiratory failure. The company is also developing NRX-100/101, the first sequential drug regimen for bipolar depression in patients with acute suicidal ideation and behavior.

NRX Pharmaceuticals Inc

Sen. Bernie Sanders (I-Vt.) is not shy when it comes to <a href="https://www.benzinga.com/25/04/44818213/bernie-sanders-rallies-against-trump-musk-at-coachella-economy-that-is-working-very-well-for-the-billionaire-class">speaking out about the corruption </a>within politics and his thoughts about President Donald Trump and billionaire Elon Musk.
When asked what he would do as president on his first day in office, the two key figures may have been on his mind.
Sanders as President: Sanders ran as president in the 2016 and 2020 elections, finishing runner-up in the <a href="https://www.benzinga.com/general/politics/24/08/40497250/dnc-night-2-takeaways-bernie-sanders-attacks-billionaires-obamas-call-for-history-to-be-made">Democratic Party primary </a>both times.
While Sanders may never run as president again, he couldn't help but share his answer for the hypothetical question of what he would do in office first, as <a href="https://nypost.com/2025/06/24/media/joe-rogan-asks-bernie-sanders-if-he-will-run-for-president-again-what-he-would-do-on-day-one/">reported </a>by the New York Post.
During an appearance on the &#8220;Joe Rogan Experience&#8221; podcast, host Joe Rogan asked Sanders, "What would you have done the first day in office?"
The question came after Rogan alluded to Sanders getting "derailed" in the 2016 election and having the party conspire against him.
After asking how many hours he had to explain his answer of what he would do in the first day, Sanders provided his best answer.
"Well, it's not just the first day in office," Sanders said. "I would have dealt with this campaign finance reform issue."
Sanders told Rogan it would be better for elections to be funded by the government giving every candidate the same amount of money to spend.
"Makes a lot more sense than having billionaires fund elections, which is what you got right now."
Sanders comments seemed to hint at the hundreds of millions of dollars donated by Tesla CEO Musk to help Trump win the 2024 presidential election.
The Senator brushed off concerns about taxpayers paying for the campaigns, saying it would be better than the current alternative.
"So all I'm saying is you got a corrupt campaign finance system, on both sides, which is rejecting the will of the American people and end up supporting powerful special interests," Sanders said. "And if we do not get a handle on that issue, I worry very much about the future of American democracy."
Did You Know?
<ul class="wp-block-list">
<li>Congress Is Making Huge Investments. <a href="https://www.benzinga.com/gov-trades/?utm_source=BZprocontent062525">Get Tips On What They Bought And Sold With Our Easy-to-Use Tool</a></li>
</ul>
Sanders Pushing for Change: Rogan asked Sanders if he would run for president again during the interview.
"I am 83 years of age. I'm not sure the American people would be too enthusiastic," Sanders answered.
Rogan didn't dismiss the idea, adding that Sanders was very "with it" and only a couple of years older than former President Joe Biden.
"Think of that. You could be off a lot worse," Rogan said.
Sanders, who didn't specifically rule out a run as president again, highlighted his "Fight Oligarchy" tour across the country that has shown support from both major political parties.
"There is growing dissatisfaction with the current politics in America, both parties, and people want a new vision, and people want a new vision for America."
Read Next: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/tech/25/06/45968055/bernie-sanders-says-ai-boom-must-serve-working-families-not-billionaires-calls-for-shorter-work-week-higher-quality-of-life">Bernie Sanders Says AI Boom Must Serve Working Families, Not Billionaires: Calls For Shorter Work Week, Higher Quality Of Life</a></li>
</ul>
Photo: Shutterstock

Politics

Bernie Sanders Shares First Thing He Would Do As President — And It Could Be A Jab At Elon Musk

Green Brick Partners (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GRBK#NYSE">GRBK</a>) has outperformed the market over the past 5 years by 24.87% on an annualized basis producing an average annual return of 39.38%. Currently, Green Brick Partners has a market capitalization of $2.77 billion. 
Buying $100 In GRBK: If an investor had bought $100 of GRBK stock 5 years ago, it would be worth $559.61 today based on a price of $62.30 for GRBK at the time of writing.
<h3>Green Brick Partners's Performance Over Last 5 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1750890612_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

News

Trading Ideas

GRBK

Here's How Much $100 Invested In Green Brick Partners 5 Years Ago Would Be Worth Today

Deere (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DE#NYSE">DE</a>) has outperformed the market over the past 5 years by 11.87% on an annualized basis producing an average annual return of 26.38%. Currently, Deere has a market capitalization of $138.01 billion. 
Buying $1000 In DE: If an investor had bought $1000 of DE stock 5 years ago, it would be worth $3,296.73 today based on a price of $506.74 for DE at the time of writing.
<h3>Deere's Performance Over Last 5 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1750889721_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

$1000 Invested In This Stock 5 Years Ago Would Be Worth This Much Today

Electric vehicle company BYD Co. (OTC:<a class="ticker" href="https://www.benzinga.com/stock/BYDDY#OTC">BYDDY</a>)(OTC:<a class="ticker" href="https://www.benzinga.com/stock/BYDDF#OTC">BYDDF</a>) <a href="https://www.benzinga.com/25/05/45564693/byd-outsells-elon-musks-tesla-amid-european-plans-shift-into-gear">has surpassed </a>Tesla Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>) in Europe and the trend may continue with multiple new vehicle launches.
What Happened: In recent months, BYD has overtaken Tesla in unit sales in Europe, a move that could be two-fold, from new vehicle launches by BYD and <a href="https://www.benzinga.com/markets/tech/25/06/46087914/teslas-europe-sales-slide-for-5th-straight-month-elon-musk-led-ev-giants-market-share-shrinks-to-1-3">declining demand for Tesla.</a>
In terms of new vehicle launches, BYD may only be getting started, according to a report from <a href="https://electrek.co/2025/06/24/byd-flooding-europe-with-new-evs-faster-than-any-carmaker/">Electrek</a>.
BYD plans to release new vehicles faster than any other automotive company in Europe. This includes launching the Dolphin Surf EV that starts at less than $25,000 in the region, becoming one of the most affordable electric vehicles in the area.
BYD Special Advisor for Europe Alfredo Altavilla highlighted the Dolphin Surf being one of the company's missing pieces as it looks to compete with the cheapest EVs in the region.
"We have been launching six cars in less than a year," Altavilla said. "We are covering all of the most important segments of the European car market."
Not all of BYD's new vehicles are low-cost models, with some of the company's new launches are under the Denza Yangwang brand, which is BYD's luxury unit.
"I have zero problem in saying I don't think there has ever been such a product offensive done in Europe as the one BYD is doing," Altavilla added.
Altavilla said the team is getting together after the summer break and will have more reveals before the end of the year.
Read Also: <a href="https://www.benzinga.com/news/management/25/05/45176283/warren-buffett-is-getting-richer-in-2025-and-its-not-because-of-apple-how-one-chinese-holding-is-helping">Warren Buffett Is Getting Richer In 2025 — And It&#8217;s Not Because Of Apple: How One Chinese Holding Is Helping</a>
Why It's Important: BYD is outselling Tesla in Europe and in 2024 beat Tesla in global EV sales for the first time. As new models are released, that momentum could continue.
BYD will begin production on a new manufacturing plant in Hungary by the end of 2025, which will boost production in the region and allow for more customization.
"As we go forward into 2026, more and more of the BYD line-up will be specific to this region," Altavilla said.
BYD could more than double its sales in Europe this year to around 186,000, according to S&amp;P Global Mobility. In four more years, the sales could double again to 400,000 in Europe.
BYD Price Action: BYD stock (BYDDY) closed Wednesday down 2.28% at $98.56 versus a 52-week trading range of $52.50 to $120.30. BYD stock is up 48% year-to-date in 2025.
Read Next: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/tech/25/06/45855643/tesla-rival-byd-launches-15000-seal-06-sedan-as-chinas-ev-price-war-heats-up">Tesla Rival BYD Launches $15,000 Seal 06 Sedan As China&#8217;s EV Price War Heats Up</a></li>
</ul>
Photo: 2025 BYD DOLPHIN SURF ACTION 007, courtesy BYD

Eurozone

Global

BYDDF

BYDDY

TSLA

BYD Beats Tesla In Europe: Never Been 'Such A Product Offensive Done'

Raymond James Finl (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RJF#NYSE">RJF</a>) has outperformed the market over the past 10 years by 2.92% on an annualized basis producing an average annual return of 14.34%. Currently, Raymond James Finl has a market capitalization of $30.61 billion. 
Buying $100 In RJF: If an investor had bought $100 of RJF stock 10 years ago, it would be worth $383.54 today based on a price of $151.73 for RJF at the time of writing.
<h3>Raymond James Finl's Performance Over Last 10 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1750888846_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Here's How Much $100 Invested In Raymond James Finl 10 Years Ago Would Be Worth Today

Looking into the current session, Dayforce Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DAY#NYSE">DAY</a>) shares are trading at $55.00, after a 4.76% drop. Over the past month, the stock decreased by 4.65%, but over the past year, it actually went up by 10.66%. With questionable short-term performance like this, and great long-term performance, long-term shareholders might want to start looking into the company's price-to-earnings ratio. 

<img src="https://www.benzinga.com/files/images/story/2025/1750888815_0.png" alt="Past Year Chart" />

<h3>Comparing Dayforce P/E Against Its Peers</h3>
The P/E ratio is used by long-term shareholders to assess the company's market performance against aggregate market data, historical earnings, and the industry at large. A lower P/E could indicate that shareholders do not expect the stock to perform better in the future or it could mean that the company is undervalued. 
Compared to the aggregate P/E ratio of 32.84 in the Professional Services industry, Dayforce Inc. has a higher P/E ratio of 360.94. Shareholders might be inclined to think that Dayforce Inc. might perform better than its industry group. It's also possible that the stock is overvalued. 

<img src="https://www.benzinga.com/files/images/story/2025/1750888815_1.png" alt="Guage" />

In summary, while the price-to-earnings ratio is a valuable tool for investors to evaluate a company's market performance, it should be used with caution. A low P/E ratio can be an indication of undervaluation, but it can also suggest weak growth prospects or financial instability. Moreover, the P/E ratio is just one of many metrics that investors should consider when making investment decisions, and it should be evaluated alongside other financial ratios, industry trends, and qualitative factors. By taking a comprehensive approach to analyzing a company's financial health, investors can make well-informed decisions that are more likely to lead to successful outcomes.

Intraday Update

Markets

A Look Into Dayforce Inc's Price Over Earnings

Taiwan's largest company, Taiwan Semiconductor Manufacturing Co's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TSM#NYSE">TSM</a>) overseas unit, Taiwan Semiconductor Global, is facing a currency risk &#8211; the Taiwanese dollar is strengthening against the now volatile and weakening U.S. dollar.
TSMC Global Ltd. <a target="_blank" href="https://www.benzinga.com/topic/tsmc" rel="noreferrer noopener">is preparing</a> to raise $10 billion by issuing new shares to manage currency volatility and maintain capital flexibility.
TSMC is the primary chip supplier for tech giants like Nvidia Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>), Apple Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAPL#NASDAQ">AAPL</a>) and Microsoft Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSFT#NASDAQ">MSFT</a>).
Also Read: <a target="_blank" href="https://www.benzinga.com/markets/tech/25/06/45859582/nvidia-supplier-taiwan-semiconductor-posts-40-topline-growth-in-may-stock-surges" rel="noreferrer noopener">Nvidia Supplier Taiwan Semiconductor Posts 40% Topline Growth In May, Stock Surges</a>
<h2 class="wp-block-heading">What Happened</h2>
The share issuance plan was first reported <a target="_blank" href="https://www.bloomberg.com/news/articles/2025-06-25/tsmc-unit-to-issue-10-billion-of-stock-to-counter-forex-swings?taid=685bd6ec8217380001328131&amp;utm_campaign=trueanthem&amp;utm_content=business&amp;utm_medium=social&amp;utm_source=twitter&amp;sref=TBDibEcD" rel="noreferrer noopener">to Bloomberg</a>. TSMC Global Ltd., the offshore unit of Taiwan Semiconductor Manufacturing Co., will issue the stock to support foreign exchange hedging operations.
This marks the third such equity move since 2024, and it is the largest to date. The timing coincides with the recent appreciation of the Taiwan dollar.
The central bank has warned against speculation after the currency's sharp rise in May, which marked its largest single-day gain since the 1980s.
Analyst Philip McNicholas from Robeco told Bloomberg that the rising volatility may be prompting banks to reassess margin requirements, making capital injections from share issuances a useful tool for companies.
TSMC's CEO C. C. Wei informed shareholders this month that the stronger currency has reduced the firm's operating margin by several percentage points.
Taiwan Semiconductor stock surged 28% in the last 12 months. The chipmaker has also <a target="_blank" href="https://www.benzinga.com/markets/tech/25/06/45953943/taiwan-semiconductor-eyes-rollout-of-2nm-advanced-tech-chips-this-year" rel="noreferrer noopener">explored commercializing its</a> advanced 2-nanometer process&nbsp;using gate-all-around (GAA) technology in the second half of 2025. It plans to start 2-nm production simultaneously at its Baoshan and Kaohsiung facilities within Taiwan's Hsinchu Science Park.
In April, Taiwan Semiconductor <a target="_blank" href="https://www.benzinga.com/25/04/44857887/taiwan-semiconductor-q1-surges-41-in-sales-boosted-by-ai-chip-demand-expanded-margins" rel="noreferrer noopener">reported&nbsp;first-quarter</a> net sales&nbsp;of $25.53 billion, up 41.6% year-over-year, topping the analyst consensus estimate of $23.92 billion. However, net sales declined&nbsp;3.4% quarter over quarter. Taiwan Semiconductor&nbsp;guided second-quarter&nbsp;2025 revenue of $28.4 billion-$29.2 billion, versus the $26.79&nbsp;billion analyst estimate.&nbsp;
Price Action: TSM stock gained by 1.20% to $222.74 on Wednesday.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/analyst-stock-ratings/reiteration/25/06/46100456/tesla-robotaxi-scaling-growth-will-be-slow-in-near-term-goldman-sachs" target="_blank" rel="noreferrer noopener">Tesla Robotaxi Scaling Growth Will Be Slow In Near Term: Goldman Sachs</a></li>
</ul>
Photo by Jack Hong via Shutterstock

Asia

Offerings

Tech

Media

AAPL

MSFT

NVDA

SSNLF

Nvidia Supplier Taiwan Semiconductor Wants To Raise $10 Billion For This Risk It Cannot Control

<a href="https://www.sec.gov/Archives/edgar/data/1937987/000121390025057855/ea0247024-424b3_falcons.htm">https://www.sec.gov/Archives/edgar/data/1937987/000121390025057855/ea0247024-424b3_falcons.htm</a>

General

FBYD

Falcon's Beyond Global Files For Resale From Time To Time By Selling Securityholders Of Up To 109.8M Shares Of Class A Common Stock

Welltower (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WELL#NYSE">WELL</a>) has outperformed the market over the past 20 years by 2.54% on an annualized basis producing an average annual return of 10.97%. Currently, Welltower has a market capitalization of $99.49 billion. 
Buying $100 In WELL: If an investor had bought $100 of WELL stock 20 years ago, it would be worth $803.72 today based on a price of $153.43 for WELL at the time of writing.
<h3>Welltower's Performance Over Last 20 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1750887911_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

WELL

If You Invested $100 In This Stock 20 Years Ago, You Would Have This Much Today

<a href="https://www.bloomberg.com/news/articles/2025-06-25/enbridge-enb-says-new-canadian-pipeline-would-require-legal-changes">https://www.bloomberg.com/news/articles/2025-06-25/enbridge-enb-says-new-canadian-pipeline-would-require-legal-changes</a>

'Enbridge Says New Canadian Oil Pipeline Would Require Legal Changes First'- Bloomberg

Microsoft, In Collaboration With The Wisconsin Economic Development Corporation, The University Of Wisconsin-Milwaukee And TitletownTech Announces The Opening Of An AI Co-Innovation Lab On The UWM campus

<a href="https://www.sec.gov/Archives/edgar/data/1775734/000164117225016507/form8-k.htm">https://www.sec.gov/Archives/edgar/data/1775734/000164117225016507/form8-k.htm</a>

Management

BENF

Brad Heppner Resigns as CEO and Chairman of Beneficient, Effective Immediately as of June 19, 2025

Mastercard (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MA#NYSE">MA</a>) has outperformed the market over the past 15 years by 12.04% on an annualized basis producing an average annual return of 24.61%. Currently, Mastercard has a market capitalization of $499.22 billion. 
Buying $100 In MA: If an investor had bought $100 of MA stock 15 years ago, it would be worth $2,754.97 today based on a price of $549.70 for MA at the time of writing.
<h3>Mastercard's Performance Over Last 15 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1750887094_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Here's How Much $100 Invested In Mastercard 15 Years Ago Would Be Worth Today

Alimentation Couche-Tard (TSX:<a class="ticker" href="https://www.benzinga.com/stock/ATD#TSX">ATD</a>) reported quarterly earnings of $0.46 per share. This is a 4.17 percent decrease over earnings of $0.48 per share from the same period last year. The company reported $16.271 billion in sales this quarter. This is a 7.51 percent decrease over sales of $17.593 billion the same period last year.

Earnings

TSX:ATD

Alimentation Couche-Tard Q4 Adj. EPS $0.46 Down From $0.48 YoY, Sales $16.271B Down From $17.593B YoY

<a href="https://www.sec.gov/Archives/edgar/data/1814215/000095017025090023/buru-20250620.htm">https://www.sec.gov/Archives/edgar/data/1814215/000095017025090023/buru-20250620.htm</a>

BURU

Nuburu Says Financial Statements As Of March 31 Should No Longer Be Relied Upon Due To Misstatements; Will Restate Financial Statements As Of March 31 To Make Necessary Corrections

WOLF

Ralliant To Replace Wolfspeed In S&P 600 On July 1; Fortive Is Spinning Off Ralliant In A Transaction Expected To Be Completed On June 30; Fortive Will Remain In The S&P 500 Post Spin-off

SmartStop Self Storage REIT Announces The Acquisition Of A Class A Self-Storage Facility In Vancouver, British Columbia; No Terms Disclosed

<a href="https://www.sec.gov/Archives/edgar/data/1842939/000095017025090015/xage-20250624.htm">https://www.sec.gov/Archives/edgar/data/1842939/000095017025090015/xage-20250624.htm</a>

GBCI

GNTY

Guaranty Bancshares Says If Deal Terminated Under Certain Circumstances, Co To Pay Termination Fee Of $18.5M To Glacier Bancorp

Bit Digital Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BTBT#NASDAQ">BTBT</a>) shares are falling in Wednesday&#8217;s after-hours session after the company announced <a href="https://www.benzinga.com/pressreleases/25/06/n46103338/bit-digital-inc-announces-commencement-of-public-offering-of-its-ordinary-shares">a public offering</a>.
What To Know: Bit Digital said it commenced an underwritten public offering of ordinary shares. The company did not provide details of the offering, but said it plans to use net proceeds to purchase Ethereum (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/eth/usd">ETH</a>).
In connection with the offering, Bit Digital said it initiated a strategic transition to become a pure-play Ethereum staking and treasury company.
Bit Digital started buying Ethereum in 2022. The company held a total of 24,432.2 ETH as of March 31. Bit Digital also held 417.6 Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) as of the end of March. The company plans to convert its Bitcoin holdings into Ethereum over time as it winds down its Bitcoin mining operations.
After market close on Wednesday, Bit Digital also announced it confidentially submitted a draft registration statement with the SEC related to a proposed initial public offering of its subsidiary WhiteFiber. The company has not yet determined the number of shares to be offered or the price range for the proposed IPO.
BTBT Price Action: <a href="http://benzinga.com/quote/btbt">Bit Digital shares</a> are down nearly 20% year-to-date. The crypto stock was down 3.40% in after-hours, trading at $2.27 at the time of publication Wednesday, per <a href="http://pro.benzinga.copm">Benzinga Pro</a>.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/trading-ideas/movers/25/06/46098386/bitcoin-mining-stock-cleanspark-clsk-is-surging-wednesday-whats-going-on">Bitcoin Mining Stock CleanSpark (CLSK) Is Surging Wednesday: What&#8217;s Going On?</a></li>
</ul>
Photo: Shutterstock.

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

Movers

$BTC

$ETH

BTBT

Bit Digital Stock Falls As Company Ditches Bitcoin For Ethereum

Longevity Health Holdings, Inc. - Common Stock

XAGE

Longevity Health Merger Agreement Deadline Extended To July 8, 2025; Merger Agreement To Terminate On July 8, 2025 If Not Extended

Press Releases

HOPE Therapeutics, Inc. a subsidiary of NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Announces Signing of Term Sheet for $7.8 Million Debt Financing to Fuel HOPE Clinic Acquisitions

NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Reports First Quarter 2025 Financial Results and Provides Corporate Update

Small Cap

NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) and HOPE Therapeutics™, Inc. Selected to Present at the Wall Street Conference on May 21, 2025, in Palm Beach, Florida

NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Files Abbreviated New Drug Application (ANDA) for Preservative-Free IV Ketamine

$750 Million Market Projected to Reach $3.35 Billion Globally in 2034 for Abbreviated New Drug Application Filed on Preservative-Free IV Ketamine: NRx Pharmaceuticals, Inc. (Nasdaq: NRXP)

NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) and HOPE Therapeutics, Inc. to Present at H.C. Wainwright 6th Annual Neuro Perspectives Hybrid Conference

NRx Pharmaceuticals, Inc. (NASDAQ: NRXP) and HOPE Therapeutics, Inc. Announce Strategic Investor Relations Partnership with astr partners

NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Announces Filing of Commissioner's National Priority Voucher Application for Intravenous Ketamine (NRX-100)

"Mag 7 Undercard Movers: IBO, SNYR, CTOR, PNPN.V, LAB – Breakthroughs in Military Defense, Tech, Medical & Healthcare Fuel Market Buzz"

IBN Initiates Coverage of NRx Pharmaceuticals Inc.

AIFF

ARAI

CTOR

ILMN

NRXP

PNPNF

PRSO

SNYR

TSXV:PNPN

Anebulo Pharmaceuticals, Inc. - Common Stock

Anebulo Pharmaceuticals

Alto Neuroscience

AN2 Therapeutics

Assertio Holdings

Clearside Biomedical, Inc. - Common Stock

Clearside Biomedical

Context Therapeutics

Cumberland Pharmaceuticals Inc. - Common Stock

Cumberland

Eyenovia

Grace Therapeutics

Ikena Oncology

Iterum Therapeutics

Jupiter Neurosciences, Inc. - Common Stock

Jupiter Neurosciences

Milestone Pharmaceuticals Inc. - Common Shares

Milestone Pharmaceuticals

NeOnc Technologies Holdings, Inc. - Common Stock

NeOnc Technologies

Nutriband

Oramed Pharmaceuticals Inc. - Common Stock

Oramed Pharmaceuticals

Pliant Therapeutics

Rafael Holdings, Inc. Class B Common Stock

Rafael Holdings

Reviva Pharmaceuticals Holdings, Inc. - Common Stock

Reviva Pharmaceuticals

Cassava Sciences

Scilex Holding

SCYNEXIS

Telomir Pharmaceuticals, Inc. - Common Stock

Telomir Pharmaceuticals

Universe Pharmaceuticals Inc - Ordinary Shares

Universe Pharmaceuticals

Verrica Pharmaceuticals Inc. - Common Stock

Comments

NRX Pharmaceuticals

NRX Pharmaceuticals (NRXP) 옵션

NRX Pharmaceuticals (NASDAQ:NRXP) 주식, 옵션 체인

뉴스

파트너 / 기고자

벤징가 글로벌